Marshall Financial Group LLC Trims Holdings in Eli Lilly and Company (NYSE:LLY)

Marshall Financial Group LLC lowered its position in Eli Lilly and Company (NYSE:LLY) by 2.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 4,232 shares of the company’s stock after selling 100 shares during the period. Eli Lilly and Company makes up approximately 1.1% of Marshall Financial Group LLC’s investment portfolio, making the stock its 19th largest holding. Marshall Financial Group LLC’s holdings in Eli Lilly and Company were worth $3,832,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. Raymond James & Associates lifted its stake in Eli Lilly and Company by 9.5% in the 2nd quarter. Raymond James & Associates now owns 1,024,304 shares of the company’s stock valued at $927,384,000 after buying an additional 88,549 shares in the last quarter. MBL Wealth LLC lifted its position in shares of Eli Lilly and Company by 2.4% in the second quarter. MBL Wealth LLC now owns 1,389 shares of the company’s stock valued at $1,258,000 after acquiring an additional 33 shares in the last quarter. ARS Wealth Advisors Group LLC lifted its position in shares of Eli Lilly and Company by 2.2% in the second quarter. ARS Wealth Advisors Group LLC now owns 2,066 shares of the company’s stock valued at $1,870,000 after acquiring an additional 44 shares in the last quarter. OFI Invest Asset Management boosted its stake in shares of Eli Lilly and Company by 25.4% in the second quarter. OFI Invest Asset Management now owns 112,405 shares of the company’s stock worth $94,956,000 after acquiring an additional 22,771 shares during the last quarter. Finally, Oakworth Capital Inc. increased its position in shares of Eli Lilly and Company by 11.1% during the second quarter. Oakworth Capital Inc. now owns 3,805 shares of the company’s stock worth $3,445,000 after purchasing an additional 381 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 2,052 shares of the company’s stock in a transaction that occurred on Tuesday, May 28th. The shares were sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the sale, the insider now directly owns 98,554,195 shares of the company’s stock, valued at approximately $79,730,343,755. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, major shareholder Lilly Endowment Inc sold 2,052 shares of the business’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $809.00, for a total transaction of $1,660,068.00. Following the completion of the transaction, the insider now directly owns 98,554,195 shares of the company’s stock, valued at approximately $79,730,343,755. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CAO Donald A. Zakrowski sold 750 shares of the stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at approximately $5,842,821.10. The disclosure for this sale can be found here. Over the last quarter, insiders sold 1,214,704 shares of company stock valued at $1,066,841,316. 0.13% of the stock is currently owned by company insiders.

Eli Lilly and Company Trading Down 1.0 %

LLY traded down $9.46 during mid-day trading on Friday, hitting $922.12. 2,364,894 shares of the stock were exchanged, compared to its average volume of 3,096,824. The firm’s fifty day moving average is $878.93 and its two-hundred day moving average is $805.16. Eli Lilly and Company has a 1-year low of $516.57 and a 1-year high of $966.10. The company has a market cap of $876.39 billion, a PE ratio of 135.81, a PEG ratio of 1.81 and a beta of 0.41. The company has a current ratio of 1.35, a quick ratio of 1.03 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Thursday, August 15th will be given a dividend of $1.30 per share. The ex-dividend date is Thursday, August 15th. This represents a $5.20 annualized dividend and a dividend yield of 0.56%. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Analyst Upgrades and Downgrades

LLY has been the topic of a number of research reports. Jefferies Financial Group raised their price objective on Eli Lilly and Company from $994.00 to $1,015.00 and gave the company a “buy” rating in a report on Monday, June 24th. Berenberg Bank boosted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday. Bank of America upped their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the company a “buy” rating in a research note on Friday, August 9th. Deutsche Bank Aktiengesellschaft raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating and raised their target price for the stock from $725.00 to $1,025.00 in a research note on Monday, August 12th. Finally, Guggenheim upped their price target on Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a research report on Friday. Two equities research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and a consensus target price of $956.88.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.